MX2020006650A - Esketamina para el tratamiento de la depresión. - Google Patents
Esketamina para el tratamiento de la depresión.Info
- Publication number
- MX2020006650A MX2020006650A MX2020006650A MX2020006650A MX2020006650A MX 2020006650 A MX2020006650 A MX 2020006650A MX 2020006650 A MX2020006650 A MX 2020006650A MX 2020006650 A MX2020006650 A MX 2020006650A MX 2020006650 A MX2020006650 A MX 2020006650A
- Authority
- MX
- Mexico
- Prior art keywords
- depression
- esketamine
- treatment
- patient
- effective amount
- Prior art date
Links
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 title abstract 4
- 229960000450 esketamine Drugs 0.000 title abstract 4
- 208000020401 Depressive disease Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 abstract 1
- 238000011866 long-term treatment Methods 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona métodos para mantener una remisión estable o respuesta estable lograda por un paciente con depresión después de la administración de una cantidad terapéuticamente eficaz de esketamina durante una fase de administración inicial, que comprende la administración continua de una cantidad terapéuticamente eficaz de esketamina por al menos cinco meses durante una fase de administración posterior; la presente invención también proporciona métodos para el tratamiento a largo plazo de la depresión en un paciente que comprende administrar al paciente que necesita el tratamiento una cantidad terapéuticamente eficaz clínicamente probada como segura y clínicamente probada como eficaz de esketamina durante al menos seis meses; en algunas modalidades, la depresión es trastorno depresivo mayor o depresión resistente al tratamiento.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762609504P | 2017-12-22 | 2017-12-22 | |
US201862663206P | 2018-04-26 | 2018-04-26 | |
US201862663219P | 2018-04-26 | 2018-04-26 | |
US201862667406P | 2018-05-04 | 2018-05-04 | |
US201862675846P | 2018-05-24 | 2018-05-24 | |
US201862755905P | 2018-11-05 | 2018-11-05 | |
PCT/US2018/066143 WO2019126108A1 (en) | 2017-12-22 | 2018-12-18 | Esketamine for the treatment of depression |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020006650A true MX2020006650A (es) | 2020-11-06 |
Family
ID=65003585
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006650A MX2020006650A (es) | 2017-12-22 | 2018-12-18 | Esketamina para el tratamiento de la depresión. |
MX2023012450A MX2023012450A (es) | 2017-12-22 | 2020-07-13 | Esketamina para el tratamiento de la depresion. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023012450A MX2023012450A (es) | 2017-12-22 | 2020-07-13 | Esketamina para el tratamiento de la depresion. |
Country Status (16)
Country | Link |
---|---|
US (2) | US11707440B2 (es) |
EP (1) | EP3501542A1 (es) |
JP (2) | JP2021506924A (es) |
KR (2) | KR20200113197A (es) |
CN (2) | CN112423789A (es) |
AU (1) | AU2018282466A1 (es) |
BR (1) | BR112020012473A2 (es) |
CA (1) | CA3086478A1 (es) |
IL (1) | IL275482A (es) |
JO (1) | JOP20200156A1 (es) |
MA (1) | MA47719A (es) |
MX (2) | MX2020006650A (es) |
PH (1) | PH12020500555A1 (es) |
SG (1) | SG11202005896WA (es) |
TW (1) | TW202415363A (es) |
WO (1) | WO2019126108A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015022972B1 (pt) | 2013-03-15 | 2023-02-14 | Janssen Pharmaceutica Nv | Composição farmacêutica de cloridrato de s-cetamina e formas de dosagem da mesma |
WO2016044150A1 (en) | 2014-09-15 | 2016-03-24 | Janssen Pharmaceutica Nv | VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION |
US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
KR20200113197A (ko) | 2017-12-22 | 2020-10-06 | 얀센 파마슈티칼즈, 인코포레이티드 | 우울증 치료를 위한 에스케타민 |
KR20210028159A (ko) | 2018-06-27 | 2021-03-11 | 클렉시오 바이오사이언시스 리미티드 | 주요 우울 장애를 치료하는 방법 |
CN112702995A (zh) | 2018-10-05 | 2021-04-23 | 克雷西奥生物科技有限公司 | 治疗重度抑郁症的艾***的治疗方案 |
CA3131929A1 (en) | 2019-03-05 | 2020-09-10 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
AU2020324432A1 (en) * | 2019-08-05 | 2021-10-07 | The Ketamine Research Foundation | Ketamine for the treatment of postpartum symptoms and disorders |
JP2022546456A (ja) * | 2019-08-28 | 2022-11-04 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン |
AU2020345050A1 (en) * | 2019-09-13 | 2021-09-16 | Janssen Pharmaceuticals, Inc. | Intranasal administration of esketamine |
TW202135787A (zh) | 2019-12-12 | 2021-10-01 | 比利時商健生藥品公司 | 艾***調配物及製備與儲存的方法 |
WO2021137148A1 (en) | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions |
AU2021364293A1 (en) * | 2020-10-22 | 2023-06-08 | Tonix Pharmaceuticals Holding Corp. | Randomization honoring methods to assess the significance of interventions on outcomes in disorders |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10025A (en) | 1853-09-20 | Improvement in turbines | ||
CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
JPS632932A (ja) | 1986-06-23 | 1988-01-07 | Teijin Ltd | 経鼻投与用粉末状組成物 |
US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
US4994467A (en) | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
DE4312016A1 (de) | 1993-04-13 | 1994-10-20 | Goedecke Ag | Stabile Ketamin-Lösungen |
US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
DE69629108T2 (de) | 1995-02-24 | 2004-04-22 | Weg, Stuart L. | Anwendung von ketamin zur entgiftung |
JPH11511466A (ja) | 1995-08-30 | 1999-10-05 | スチュアート エル ウェグ | 苦痛を管理しおよび薬物依存性を軽減するための、ケタミンの投与 |
FR2739294B1 (fr) | 1995-09-29 | 1998-01-16 | Lhd Lab Hygiene Dietetique | Embout nasal de securite |
DE19619665C2 (de) | 1996-05-15 | 2001-03-08 | Goedecke Ag | Racemattrennung von Ketamin |
DE19723133A1 (de) | 1997-06-03 | 1998-12-10 | Caideil M P Teoranta Tourmakea | Austragvorrichtung für Medien |
FR2764807B1 (fr) | 1997-06-18 | 1999-08-20 | Valois Sa | Dispositif de distribution nasale d'un produit fluide ou pulverulent |
ES2238843T3 (es) | 1998-07-24 | 2005-09-01 | Seo Hong Yoo | Disoluciones acuosas transparentes de acidos biliares. |
US6599883B1 (en) | 1998-10-30 | 2003-07-29 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of xylitol |
US6176242B1 (en) | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
US6017961A (en) | 1999-07-08 | 2000-01-25 | Flores; John Anthony | Ketamine and n-butyl-p-aminobezoate in PLO |
EP1103256A1 (de) | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom |
CA2423354C (en) | 2000-09-20 | 2009-12-15 | Lee Shahinian Jr. | Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications |
US6881731B1 (en) | 2000-10-23 | 2005-04-19 | Shanbrom Technologies, Llc | Enhancers for microbiological disinfection |
WO2004010932A2 (en) | 2002-07-30 | 2004-02-05 | Peter Migaly | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
EP2027854A1 (en) | 2002-11-18 | 2009-02-25 | Yaupon Therapeutics, Inc. | Analgesic uses of norketamine and ketamine/norketamine prodrugs |
US7687080B2 (en) | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
US8082173B2 (en) | 2003-05-22 | 2011-12-20 | Cecil Kost | Drug sample fulfillment architecture |
US20050095277A1 (en) | 2003-06-25 | 2005-05-05 | Binnur Ozturk | Neuropathy cream |
US20040265364A1 (en) | 2003-06-25 | 2004-12-30 | Binnur Ozturk | Neuropathy cream |
US20060223788A1 (en) | 2005-03-29 | 2006-10-05 | Cathcart Clifton H | Analgesic composition for topical use |
EP2526987A3 (en) | 2005-06-01 | 2013-04-24 | SHL Group AB | Device for delivering medicament |
US20060276550A1 (en) | 2005-06-03 | 2006-12-07 | Dileep Bhagwat | Topical compositions of ketamine and butamben and methods of their use |
WO2007111880A2 (en) | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
WO2007123945A2 (en) | 2006-04-21 | 2007-11-01 | Aradigm Corporation | Mechanical single dose intrapulmonary drug delivery devices |
KR20090029200A (ko) | 2006-05-22 | 2009-03-20 | 반다 파마슈티칼즈, 인코퍼레이티드. | 우울증 질환에 대한 치료 |
DE102007009888A1 (de) | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
US7745665B2 (en) | 2007-06-04 | 2010-06-29 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines |
US8710070B2 (en) | 2008-03-27 | 2014-04-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
US20120225949A1 (en) | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
PL2582366T3 (pl) | 2010-06-15 | 2016-04-29 | Gruenenthal Gmbh | Kombinacja farmaceutyczna do leczenia bólu |
WO2013003669A2 (en) | 2011-06-30 | 2013-01-03 | University Of South Florida | Compositions, methods of use, and methods of treatment |
CN104395283A (zh) | 2011-10-14 | 2015-03-04 | 美国政府健康及人类服务部 | (2r,6r)-羟基去甲***、(s)-脱氢去甲***以及(r,s)-***的其他立体异构脱氢和羟基化代谢物在治疗忧郁症和神经性疼痛中的应用 |
JP6285865B2 (ja) | 2011-11-14 | 2018-02-28 | アルファシグマ ソシエタ ペル アチオニ | うつ病を有する対象のための処置レジメンを選択するためのアッセイ及び方法 |
US20130209585A1 (en) | 2012-02-13 | 2013-08-15 | Stanley Kim | Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy |
WO2013138322A1 (en) | 2012-03-12 | 2013-09-19 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
AU2016203771A1 (en) | 2012-03-13 | 2016-06-23 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
EP2830604A4 (en) | 2012-03-30 | 2015-08-19 | Gen Hospital Corp | COMPOSITIONS WITH SCOPOLAMINE AND KETAMINE FOR THE TREATMENT OF DEPRESSIONS |
WO2014020155A1 (en) | 2012-08-02 | 2014-02-06 | Clinpharm Reform Gmbh | Oral transmucosal adminstration forms of s-ketamine |
EP2887930A4 (en) | 2012-08-23 | 2016-03-23 | Stuart L Weg | ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE |
FR2994844B1 (fr) | 2012-08-31 | 2015-01-02 | Assist Publ Hopitaux De Paris | Formulation gelifiante a base de ketamine |
NZ619257A (en) | 2012-10-08 | 2015-07-31 | Auckland Uniservices Ltd | Ketamine derivatives |
ES2484068B1 (es) | 2013-02-08 | 2015-04-16 | Ana MÍNGUEZ MARTÍ | Una composición farmacéutica que contiene ketamina y amitriptilina |
EP2983787B1 (en) | 2013-04-12 | 2019-10-02 | Icahn School of Medicine at Mount Sinai | Method for treating post-traumatic stress disorder |
US9913803B2 (en) | 2013-08-26 | 2018-03-13 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
EP3964203A1 (en) | 2013-09-13 | 2022-03-09 | National University Corporation Chiba University | Application of r-ketamine and salt thereof as pharmaceuticals |
CN103705909A (zh) | 2013-12-16 | 2014-04-09 | 陈镜伊 | 一种无痛人流用药 |
WO2015101693A1 (es) | 2013-12-31 | 2015-07-09 | Servicio Andaluz De Salud | Composiciones y preparaciones combinadas para el tratamiento de las algias orofaríngeas |
EP3094312B1 (en) | 2014-01-14 | 2019-03-13 | Children's Hospital Medical Center | Compositions comprising ketamine for treating an autism spectrum disorder |
HUE044928T2 (hu) | 2014-04-17 | 2019-11-28 | Develco Pharma Schweiz Ag | Ketamin orális dózisformája |
CN106470559A (zh) | 2014-05-04 | 2017-03-01 | 弗门尼舍有限公司 | 经调味的食品和饮料产品 |
FR3023188B1 (fr) | 2014-07-04 | 2016-08-19 | Aptar France Sas | Dispositif de distribution de produit fluide. |
MX2017001908A (es) | 2014-08-13 | 2017-08-08 | Janssen Pharmaceutica Nv | Metodo para el tratamiento de la depresion. |
WO2016044150A1 (en) | 2014-09-15 | 2016-03-24 | Janssen Pharmaceutica Nv | VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION |
EP3240422A1 (en) | 2014-12-31 | 2017-11-08 | Icahn School of Medicine at Mount Sinai | Method of maintaining the anti-depressant effect of ketamine with lithium |
CN104798728A (zh) | 2015-05-08 | 2015-07-29 | 南京中医药大学 | 产后抑郁动物模型的建立方法及其应用 |
US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
US20160338977A1 (en) * | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
CN107847469A (zh) | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | ***透皮递送*** |
US20180296478A1 (en) | 2016-02-12 | 2018-10-18 | Synergistic Therapeutics, Llc | Sublingual antidepressant and antianxiety tablet |
US20180042936A1 (en) | 2016-03-18 | 2018-02-15 | Genomind, Inc. | Maintenance therapy using tianeptine |
KR20200113197A (ko) | 2017-12-22 | 2020-10-06 | 얀센 파마슈티칼즈, 인코포레이티드 | 우울증 치료를 위한 에스케타민 |
-
2018
- 2018-12-18 KR KR1020207021196A patent/KR20200113197A/ko unknown
- 2018-12-18 KR KR1020247000937A patent/KR20240011237A/ko active Application Filing
- 2018-12-18 CN CN201880090058.6A patent/CN112423789A/zh active Pending
- 2018-12-18 JO JOP/2020/0156A patent/JOP20200156A1/ar unknown
- 2018-12-18 JP JP2020534520A patent/JP2021506924A/ja active Pending
- 2018-12-18 MX MX2020006650A patent/MX2020006650A/es unknown
- 2018-12-18 CA CA3086478A patent/CA3086478A1/en active Pending
- 2018-12-18 SG SG11202005896WA patent/SG11202005896WA/en unknown
- 2018-12-18 WO PCT/US2018/066143 patent/WO2019126108A1/en active Application Filing
- 2018-12-18 BR BR112020012473-7A patent/BR112020012473A2/pt unknown
- 2018-12-18 US US16/956,403 patent/US11707440B2/en active Active
- 2018-12-18 CN CN202311355796.8A patent/CN117531017A/zh active Pending
- 2018-12-21 AU AU2018282466A patent/AU2018282466A1/en active Pending
- 2018-12-21 MA MA047719A patent/MA47719A/fr unknown
- 2018-12-21 EP EP18215651.3A patent/EP3501542A1/en active Pending
- 2018-12-21 TW TW112130258A patent/TW202415363A/zh unknown
-
2020
- 2020-06-18 PH PH12020500555A patent/PH12020500555A1/en unknown
- 2020-06-18 IL IL275482A patent/IL275482A/en unknown
- 2020-07-13 MX MX2023012450A patent/MX2023012450A/es unknown
-
2023
- 2023-07-05 US US18/347,393 patent/US20240000728A1/en active Pending
- 2023-10-06 JP JP2023174444A patent/JP2024001204A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2020123893A3 (es) | 2022-04-29 |
MX2023012450A (es) | 2023-10-31 |
KR20200113197A (ko) | 2020-10-06 |
MA47719A (fr) | 2020-01-15 |
PH12020500555A1 (en) | 2021-05-17 |
AU2018282466A1 (en) | 2019-07-11 |
US20240000728A1 (en) | 2024-01-04 |
CN112423789A (zh) | 2021-02-26 |
JP2021506924A (ja) | 2021-02-22 |
JP2024001204A (ja) | 2024-01-09 |
CA3086478A1 (en) | 2019-06-27 |
EP3501542A1 (en) | 2019-06-26 |
TW202415363A (zh) | 2024-04-16 |
TW201940162A (zh) | 2019-10-16 |
JOP20200156A1 (ar) | 2022-10-30 |
WO2019126108A1 (en) | 2019-06-27 |
US11707440B2 (en) | 2023-07-25 |
SG11202005896WA (en) | 2020-07-29 |
CN117531017A (zh) | 2024-02-09 |
BR112020012473A2 (pt) | 2020-11-24 |
IL275482A (en) | 2020-08-31 |
KR20240011237A (ko) | 2024-01-25 |
RU2020123893A (ru) | 2022-01-24 |
US20210386688A1 (en) | 2021-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
MX2019012884A (es) | Terapia de combinacion. | |
MX2022011334A (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert. | |
MX2021000289A (es) | Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia. | |
MY201105A (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
MX2021002321A (es) | Nuevos metodos. | |
HRP20211824T1 (hr) | Modulatori aktivnosti komplementa | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
PH12017500392A1 (en) | Medical treatments based on anamorelin | |
EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
MX2022000143A (es) | Metodos novedosos. | |
EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
MY193963A (en) | Composition for treating joint diseases and kit containing same | |
BR112017002449A2 (pt) | tratamento de sintomas associados com terapia de privação androgênica | |
PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
MX2016011002A (es) | Tratamiento de angioedema hereditario con inhibidor c1. | |
BR112018002433A2 (pt) | composição farmacêutica para tratamento da enxaqueca | |
UA111312C2 (uk) | Спосіб лікування гострого коронарного синдрому без елевації сегмента st у пацієнтів з ішемічною хворобою серця та метаболічним синдромом, що перенесли перкутанну транслюмінарну коронарну ангіопластику | |
UA115063U (xx) | Спосіб лікування собак із больовим синдромом при панкреатиті | |
EA201991119A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
AR103764A1 (es) | Pridopidina como mejoradora de la función cognitiva y en el tratamiento de la enfermedad de alzheimer | |
UA104030U (uk) | Спосіб лікування хворих із загостренням хронічного бронхіту вірусної етіології |